Search Results

Hormone Replacement Therapy (HRT) has long been a go-to treatment for relieving the uncomfortable symptoms of menopause—hot flashes, night sweats, mood swings, and vaginal dryness. But for many women, the decision to use HRT comes with a critical question: does HRT increase the risk of breast cancer? The answer is complex and depends on several…

Popping a few burgers or steaks on the grill can be a fun and relaxing way to enjoy summer with family and friends, but some methods of grilling are riskier than others. Cooking with charcoal or cooking your meat incorrectly may be linked to an increased risk of cancer—but there’s no need to avoid the…

On May 20, The Network’s government relations team and Maryland Oncology Hematology (MOH) attended a bill signing ceremony at the Maryland State Capitol. During the ceremony, Maryland Governor Wes Moore signed HB 1243 and SB 975 into law, which will permit cancer patients to access specialty drugs from community oncology practices and limit interference from…

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium and Longitudinal Prospective Study (MYLUNG Program: Part 3) Order-Set-Go: Increasing Biomarker Testing Rates in Patients with Non-small-cell Lung Cancer Through Use of Clinical Decision Support Tools (MYLUNG/23329/LUN 576) Brief Summary: This longitudinal study looks to quantify the testing timeline, operational barriers, and…

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, in Patients with Advanced or Recurrent Endometrial Cancer (FTH-PIK-201) MOA: PIKTOR is a combination of sapanisertib, an mTORC1 and 2 inhibitor, and serabelisib, a PI3Kα inhibitor. Key Eligibility Criteria: Histologically…